Skip to main content

Table 4 Incidence of acute rejection (AR) at 3 and 12 months

From: Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients

 

Oral ganciclovir

Valganciclovir

p-value

 

3 months (n = 37)

3 months (n = 51)

 

CAR scorea, median (quartiles)

   

3 months

2 (0 – 4)

0 (0 – 2)

0.02

12 months

3 (2 – 6)

1.5 (0 – 3)

0.002

CAR score/TBBb, median (quartiles)

   

3 months

0.5 (0 - 1)

0 (0 - 0.5)

0.008

12 months

0.43 (0.2-0.67)

0.14 (0-0.5)

0.001

At least one episode of AR grade ≥ 1, % (n)

   

3 months

68% (25/37)

44% (20/45)

0.03

12 months

84% (31/37)

62% (28/45)

0.02

At least one episode of AR grade ≥ 2, % (n)

   

3 months

51% (19/37)

29% (13/45)

0.04

12 months

73% (27/37)

49% (22/45)

0.03

At least two episodes of AR grade ≥ 2, % (n)

   

3 months

24% (9/37)

13% (6/45)

n.s

12 months

41% (15/37)

20% (9/45)

0.04

Number of TBB, median (quartiles)

   

3 months

4 (3 – 4)

4 (3 – 4)

n.s

12 months

9 (8 – 9)

8 (6 – 8)

0.001

  1. aCumulative acute rejection score (CAR score) varied between 0 and 6 at 3 months and between 0 and 16 at 12 months.
  2. bCumulative acute rejection score (CAR score) divided by the number of evaluable transbronchial biopsies (TBB).